BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 1414079)

  • 1. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pregnancy in hyperprolactinemic patients].
    Ventz M; Puhlmann B; Knappe G; Gerl H; Lehmann R; Rohde W
    Zentralbl Gynakol; 1996; 118(11):610-5. PubMed ID: 9082694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microprolactinomas in males treated by transsphenoidal surgery.
    Wolfsberger S; Czech T; Vierhapper H; Benavente R; Knosp E
    Acta Neurochir (Wien); 2003 Nov; 145(11):935-40; discussion 940-1. PubMed ID: 14628197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
    Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
    Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
    Delgrange E; Duprez T; Maiter D
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperprolactinemia in the male: clinical aspects and therapy].
    Eversmann T; Eichinger R; Fahlbusch R; Rjosk HK; von Werder K
    Schweiz Med Wochenschr; 1981 Nov; 111(47):1782-9. PubMed ID: 7313648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
    Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indications for surgery in the treatment of hyperprolactinemia.
    Zacur HA
    J Reprod Med; 1999 Dec; 44(12 Suppl):1127-31. PubMed ID: 10649823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of macroprolactinomas at Auckland Hospital 1975-91.
    Wallace EA; Holdaway IM
    N Z Med J; 1995 Feb; 108(994):50-2. PubMed ID: 7885646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hook effect in prolactin immunoassays.
    Al Sifri SN; Raef H
    Saudi Med J; 2004 May; 25(5):656-9. PubMed ID: 15138537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.